Haleon Plc: 2025 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Haleon Plc (HLN)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Haleon is a global consumer health company operating in six market categories: Oral Health, Vitamins, Minerals & Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health & Other. The company operates under the "Win as One" strategy, focusing on growth, productivity, and culture transformation. In 2025, Haleon completed the full acquisition of its Tianjin TSKF joint venture in China and finalized the sell-down of Pfizer's remaining stake, becoming a fully free-float company.
Key Financial Metrics (2025 vs. 2024)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue (Reported) | £11.03 billion | £11.23 billion | (1.8)% |
| Organic Revenue Growth | 3.0% | 5.0% | -200 bps |
| Operating Profit | £2.41 billion | £2.21 billion | +9.3% |
| Adjusted Operating Profit | £2.53 billion | £2.50 billion | +1.0% |
| Organic Operating Profit Growth | 10.5% | 9.8% | +70 bps |
| Adjusted Operating Margin | 22.9% | 22.3% | +60 bps |
| Profit After Tax (Reported) | £1.67 billion | £1.44 billion | +15.6% |
| Diluted EPS (Reported) | 18.5p | 15.7p | +17.8% |
| Adjusted Diluted EPS | 18.8p | 17.9p | +5.0% |
| Free Cash Flow | £1.91 billion | £1.94 billion | (1.6)% |
| Net Debt | £7.26 billion | £7.91 billion | (8.2)% |
| Net Debt / Adjusted EBITDA | 2.6x | 2.8x | -0.2x |
Material Changes and Performance Drivers
- Revenue Headwinds: Reported revenue declined 1.8% due to foreign exchange impacts (-2.8%) and net M&A (-2.0%). Organic revenue growth of 3.0% was below medium-term guidance, primarily due to a weaker cold and flu season in Q4 and lower consumer confidence in North America.
- Margin Expansion: Adjusted gross profit margin expanded by 220 basis points at constant currency (to 65.4%) driven by pricing, net revenue management, and supply chain productivity savings. This allowed for increased investment in Advertising & Promotion (A&P) and R&D.
- Profitability: Organic operating profit grew 10.5%, driven by operating leverage and productivity initiatives. Restructuring costs decreased significantly to £89m from £214m in the prior year.
- Capital Allocation: The company returned £1.1 billion to shareholders via dividends and a £500 million share buyback. Leverage was reduced to 2.6x net debt/adjusted EBITDA.
- Category Performance:
- Oral Health: Strongest performer with 7.9% organic growth, driven by Sensodyne and parodontax.
- Respiratory Health: Reported revenue declined 11.7% (organic -1.9%) due to a weak cold/flu season and the divestment of non-US Smokers' Health business.
- VMS: Organic growth of 1.9%, with Centrum showing resilience despite North American headwinds.
Guidance, Outlook, and Risks
- 2026 Outlook: Management expects organic revenue growth of 3–5% and high single-digit adjusted operating profit growth at constant currency.
- Strategic Initiatives: In January 2026, Haleon announced a new operating model to drive agility, creating a Chief Growth Officer role and six new Operating Units. The company aims to unlock £800m in gross supply chain savings over the next five years.
- Dividend Policy: The Board proposed a final dividend of 4.9p per share (total 2025 dividend of 7.1p), representing a payout ratio of approximately 38% of adjusted earnings. A further £500m share buyback is allocated for 2026.
- Key Risks:
- Geopolitical Instability: Tensions between the US and China, and conflicts in the Middle East and Eastern Europe, pose risks to supply chains and market access.
- Supply Chain Resilience: Disruptions from extreme weather, raw material volatility, and logistics constraints.
- Regulatory & Ingredient Risks: Evolving regulations on ingredients (e.g., phenylephrine, silica) and environmental/sustainability mandates.
- Cyber Security: Increasing sophistication of cyber threats targeting healthcare data and operations.
Investor Verification Checklist
- Verify Organic Growth Drivers: Confirm the sustainability of the 3.0% organic revenue growth given the specific headwinds from the cold/flu season and North American consumer confidence.
- Supply Chain Savings Realization: Monitor the progress of the £800m supply chain savings program and the impact of the new operating model announced in January 2026.
- China JV Integration: Assess the financial impact and integration progress of the full acquisition of the TSKF joint venture in China.
- Debt Profile: Track the trajectory of net deleveraging towards the medium-term target of 2.5x net debt/adjusted EBITDA.
- Ingredient Regulatory Status: Review ongoing regulatory reviews of key ingredients (e.g., phenylephrine in the US, silica in toothpaste) and potential reformulation costs.
- Share Buyback Execution: Verify the execution of the £500m buyback program allocated for 2026.